Evidence map›Paper›PMID 27452316›Full record

SynthesisContraception2016

Contraceptive use among women with multiple sclerosis: a systematic review.

Lauren B Zapata, Titilope Oduyebo, Maura K Whiteman, Maria K Houtchens, Polly A Marchbanks, Kathryn M Curtis

Open access · greenAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Contraception, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 31 citations in OpenAlex.

  1. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2024
    Article
  2. Article
  3. Review
  4. Sex effects across the lifespan in women with multiple sclerosis.Therapeutic advances in neurological disorders · 2020
    Review
  5. Review
  6. Article
  7. Contraception for women with multiple sclerosis: Guidance for healthcare providers.Multiple sclerosis (Houndmills, Basingstoke, England) · 2017
    Review
  8. Review
  9. Article
  10. "It Would Have Been Nice to Have a Choice": Barriers to Contraceptive Decision-making among Women with Disabilities.Women's health issues : official publication of the Jacobs Institute of Women's Health
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Lauren B ZapataDivision of Reproductive Health, US Centers for Disease Control and Prevention, Chamblee, Georgia, 30341-3717. Electronic address: lzapata@cdc.gov.
Titilope OduyeboDivision of Reproductive Health, US Centers for Disease Control and Prevention, Chamblee, Georgia, 30341-3717.
Maura K WhitemanDivision of Reproductive Health, US Centers for Disease Control and Prevention, Chamblee, Georgia, 30341-3717.
Maria K HoutchensDepartment of Neurology, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
Polly A MarchbanksDivision of Reproductive Health, US Centers for Disease Control and Prevention, Chamblee, Georgia, 30341-3717.
Kathryn M CurtisDivision of Reproductive Health, US Centers for Disease Control and Prevention, Chamblee, Georgia, 30341-3717.
Centers for Disease Control and Prevention · USBrigham and Women's Hospital · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundContraception is an important consideration for women with multiple sclerosis (MS); however, little is known about the possible effects of hormonal contraception on disease progression or other adverse outcomes (e.g., thrombosis, low bone mineral density).

objectiveTo evaluate the evidence on the safety of contraceptive use among women with MS. SEARCH STRATEGY: We searched the PubMed database for peer-reviewed articles published in any language from database inception through July 2015. SELECTION CRITERIA: We included studies that examined health outcomes among women diagnosed with MS initiating or continuing a contraceptive method. We excluded case reports and case series but included all other study designs.

resultsFrom 111 articles, we identified four studies (from 5 articles) that met our inclusion criteria. Evidence from one randomized controlled trial, two retrospective cohort studies, and one cross-sectional study suggests that use of combined oral contraceptives (COCs) or oral contraceptives (OCs) (type not specified) among women with MS does not worsen the clinical course of disease, defined as disability level, disease severity or progression, relapse or number of new brain lesions on magnetic resonance imaging (body of evidence grading Level I, fair to Level II-3, poor). No studies were identified that examined the safety of other contraceptive methods or examined other outcomes of interest (venous thromboembolism, changes in bone mineral density) related to contraceptive use among women with MS.

conclusionsLimited evidence suggests that COC or OC use after MS onset does not worsen the clinical course of disease.

Indexed as

Contraception BehaviorBone DensityContraceptionContraceptives, Oral, CombinedContraceptives, Oral, HormonalDisease ProgressionFemaleHumansMultiple SclerosisRandomized Controlled Trials as TopicRisk AssessmentContraceptives, Oral, CombinedContraceptives, Oral, HormonalCombined oral contraceptivesContraceptionMultiple sclerosisOral contraceptivesSystematic review

Identifiers

PMID27452316
PMCPMC6579526
OpenAlexW2495024682

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.